|本期目录/Table of Contents|

[1]秦军,王楠,相芳,等.经皮冠状动脉介入治疗术后替格瑞洛及其代谢物浓度测定LC-MS方法的建立和应用[J].医学研究与战创伤救治(原医学研究生学报),2022,24(6):625-629.[doi:10.3969/j.issn.1672-271X.2022.06.013]
　QIN Jun,WANG Nan,XIANG Fang,et al.Establishment and application of an LC-MS method for the determination of the concentration of ticagrelor and its metabolites after percutaneous coronary intervention[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(6):625-629.[doi:10.3969/j.issn.1672-271X.2022.06.013]
点击复制

经皮冠状动脉介入治疗术后替格瑞洛及其代谢物浓度测定LC-MS方法的建立和应用()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第24卷
期数:
2022年6期
页码:
625-629
栏目:
药学研究
出版日期:
2023-01-18

文章信息/Info

Title:
Establishment and application of an LC-MS method for the determination of the concentration of ticagrelor and its metabolites after percutaneous coronary intervention
作者:
秦军; 王楠; 相芳; 初晓玲; 李祥; 陈群; 初晓倩
作者单位：210002南京，东部战区总医院秦淮医疗区（原解放军第八一医院）药剂科（秦 军、王楠、相芳、李祥、陈群、初晓倩）；210002南京，东部战区总医院（原南京军区南京总医院）药剂科（初晓玲）
Author(s):
QIN Jun1; WANG Nan1; XIANG Fang1; CHU Xiao-ling2; LI Xiang1; CHEN Qun1; CHU Xiao-qian1
（1．Department of Pharmacy，Qinhuai Medical Area，General Hospital of Eastern Theater Command，PLA，Nanjing 210002, Jiangsu, China；2．Department of Pharmacy，General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China）
关键词:
替格瑞洛; 经皮冠状动脉介入治疗术; 液质联用; 血药浓度
Keywords:
ticagrelor;  percutaneous coronary intervention;  liquid-quality combination;  blood drug concentration
分类号:
R969.1
DOI:
10.3969/j.issn.1672-271X.2022.06.013
文献标志码:
A
摘要:
目的建立测定经皮冠状动脉介入治疗术后患者血浆中替格瑞洛及其活性代谢物浓度的液相色谱串联质谱（LC-MS/MS）方法，并初步探索血浆药物浓度在此类患者中的分布特征。方法对2020年9月至2022年1月在东部战区总医院秦淮医疗区行经皮冠状动脉介入治疗术的120例急性冠脉综合征患者，口服替格瑞洛90 mg，1天2次，达到稳态后，在签署知情同意书情况下，于下次服药前1 h内采集静脉血5 mL于EP管中。采用C18色谱柱，以流动相A：0.1% 甲酸水溶液；流动相B：乙腈为流动相进行梯度洗脱，使用液相色谱-三重四极杆串联质谱仪进行检测分析，并对结果进行统计分析。结果建立了血浆中2种药物的HPLC-MS/MS测定法，血浆中杂质不干扰样品的测定，线性关系良好；高、中、低三种浓度的批间和批内变异均小于15.0%，绝对回收率在89.03%～110.10%，相对回收率在91.0%～105.69%，样品稳定性良好，符合生物样品定量分析要求。同时分析发现替格瑞洛谷浓度在≤50岁与＞60岁2组之间差异具有统计学意义（P=0.041）。结论建立了经皮冠状动脉介入治疗术后患者血浆中替格瑞洛及其活性代谢物HPLC-MS/MS测定法，方法稳定且符合生物样品定量分析要求，并成功应用于临床，为今后替格瑞洛在临床的安全及个体化应用打下基础。
Abstract:
ObjectiveThis study aimsto establish a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the determination of plasma concentrations of ticagrelor and its active metabolites in patients after percutaneous coronary intervention, and to preliminarily explore the distribution characteristics of plasma drug concentrations in such patients.MethodsA total of 120 patients with acute coronary syndrome who underwent percutaneous coronary intervention in our hospital from September 2020 to January 2022 was enrolled. After reaching steady state with oral ticagrelor 90 mg BID, 5 ml of venous blood was collected in an EP tube within 1 hour before the next dose. All patients signed informed consent. The results were analyzed using a C18 column with gradient elution using mobile phase A: 0.1% formic acid aqueous solution; mobile phase B: acetonitrile as mobile phase, and detected and analyzed using liquid chromatography-triple quadrupole tandem mass spectrometer.ResultsIn this study, an HPLC-MS/MS method for the determination of 2 drugs in plasma was established. Impurities in plasma did not interfere with the determination of the samples, and the linearity was good. the inter- and intra-batch variability was less than 15.0% for high, medium and low concentrations, and the absolute recoveries ranged from 89.03% to 110.10%, and the relative recoveries ranged from 91.0% to 105.69%. The sample stability was good and met the requirements for quantitative analysis of biological samples. The analysis also revealed a statistically significant difference in the distribution of ticagrelor Between groups ≤ 50 years oldgroup and >60 years old group（P=0.041）.ConclusionA HPLC-MS/MS method for the determination of ticagrelor and its active metabolites in plasma of patients after percutaneous coronary intervention is established. The method is stable and meets the requirements for quantitative analysis of biological samples, and has been successfully applied in clinical practice, laying the foundation for the safe and individualized application of ticagrelor in clinical practice in the future.

参考文献/References:

[1]刘江萍，木胡牙提．急性冠脉综合征流行病学及危险因素的研究进展［J］．国际心血管病杂志，2019，46（1）：1-3,7.
[2]葛均波，徐永健，王辰，等．内科学［M］．9版．北京：人民卫生出版社，2018：229-229.
[3]Moliterno DJ．Advances in antiplatelet therapy for ACS and PCI［J］．J Interv Cardiol，2008，21(Suppl 1)：S18-S24.
[4]Kamran H，Jneid H，Kayani WT，et al．Oral Antiplatelet Therapy After Acute Coronary Syndrome：A Review［J］．JAMA，2021，325（15）：1545-1555.
[5]黄晓晖，刘雪姣，周国华．氯吡格雷个体化用药研究进展［J］．医学研究生学报，2019，32（4）：443-448.
[6]Gurbel PA，Bliden KP，Butler K，et al．Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease：the ONSET/OFFSET study［J］．Circulation，2009，120（25）：2577-2585.
[7]Wallentin L，Becker RC，Budaj A，et al．Ticagrelor versus clopidogrel in patients with acute coronary syndromes［J］．N Engl J Med，2009，361（11）：1045-1057.
[8]Yang J，Qi GZ，Hu FD，et al．Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome［J］．Br J Clin Pharmacol．doi：10．1111/bcp．15422.
[9]中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等．冠心病双联抗血小板治疗中国专家共识［J］．中华心血管病杂志，2021，49（5）：432-454.
[10]ZhongW，WangX，TangL，et al．Simultaneous determination of ticagrelor and its metabolites in human plasma and urine using liquid chromatography-tandem mass spectrometry［J］．J Anal Toxicol，2016，40（6）：445-453.
[11]Peng JB，Wang YC，Li MP，et al．AnHPLC-MS/MS method for the quantitative determination of ticagrelor and its active metabolite ar-c124910xx in human plasma and its application to a clinical study［J］．CurrPharmAnal，2017，13（3）：47.
[12]柯东升，高分飞．同时测定替格瑞洛与美托洛尔血药浓度的LC-MS/MS法建立及其药代动力学研究［J］．汕头大学医学院学报，2018，31（3）：129-132,134.
[13]Xie C，Lin J，Qin Q，et al．Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome：A Meta-Analysis of Randomized Controlled Trials［J］．Anatol J Cardiol，2022，26（6）：434-441.
[14]You SC，Rho Y，Bikdeli B，et al．Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention［J］．JAMA，2020，324（16）：1640-1650.
[15]Teng R，Mitchell P，Butler K．Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals［J］．EurJ Clin Pharmacol，2012，68（8）：1175-1182.
[16]Sameer Arora，Kamal Shemisa，Muthiah Vaduganathan，et al．Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD［J］．J AmCollCardiol，2019，73（19）：2454-2464.
[17]Feit F，Voeltz MD，Attubato MJ，et al．Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2Trial［J］．Am J Cardiol，2007，100（9）：1364-1369．

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2023-01-18